Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study

BACKGROUND: Human genetic factors influence the outcome of pegylated interferon and ribavirin hepatitis C therapy. We explored the role of IL28B, APOH and ITPA SNPs on the outcomes of triple therapy including telaprevir or boceprevir in patients with compensated cirrhosis chronically infected with H...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:PLoS One
Autori principali: About, Frédégonde, Oudot-Mellakh, Tiphaine, Niay, Jonathan, Rabiéga, Pascaline, Pedergnana, Vincent, Duffy, Darragh, Sultanik, Philippe, Cagnot, Carole, Carrat, Fabrice, Marcellin, Patrick, Zoulim, Fabien, Larrey, Dominique, Hézode, Christophe, Fontaine, Hélène, Bronowicki, Jean-Pierre, Pol, Stanislas, Albert, Matthew L., Theodorou, Ioannis, Cobat, Aurélie, Abel, Laurent
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2015
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4682920/
https://ncbi.nlm.nih.gov/pubmed/26670100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0145105
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi